Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 26;6:102. doi: 10.1038/s42003-023-04485-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Schematic representation of the immunogenicity experiment with zabadinostat and spike S1 protein. Balb/c mice were treated with orally administrated zabadinostat at 25 mg/kg for 14 days (5 days on/2 days off) and intravenous spike S1 protein (days 1 and 7) with respect to vehicle-only control. Blood samples were collected on days 14, 21, and 30; n = 4 per group; b Relative body weight representation of treated and non-treated mice; n = 4; results presented as mean values +/−SD; Analysis of IgG (c) and IgM (d) spike protein antibodies at days 14, 21, and 30 in serum collected from mice treated with spike protein, zabadinostat, the combination and the control group; n = 4; results presented as mean values +/−SD; one-way ANOVA. e Analysis of spike S1-ACE2 neutralising antibodies at days 14, 21, and 30 in serum collected from mice treated with spike protein, zabadinostat, the combination, and the control group; n = 4; results presented as mean values +/−SD; one-way ANOVA.